Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc

EMBO Journal

Volumn 18, Issue 3, 1999, Pages 717-726

  Salghetti, Simone E ^a   Kim, So Young ^b   Tansey, William P ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Miz 1; Myc; Transcription; Ubiquitin mediated proteolysis

Indexed keywords

ONCOPROTEIN; UBIQUITIN;

ANIMAL CELL; ARTICLE; CANCER; CELL TRANSFORMATION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DRUG STABILITY; ENDOPEPTIDASES; GENES, MYC; HUMANS; MICE; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; TRANSCRIPTION FACTORS; UBIQUITINS;

ANIMALIA;

EID: 0033081027     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/18.3.717     Document Type: Article

References (50)

1. Alexandrov, I., Shlyakhova, L., Vartanian, A., Zajac-Kaye, M. and Alexandrova, N. (1997) c-Raf kinase binds to N-terminal domain of c-Myc. FEBS Lett., 414, 465-470.
2. Amati, B., Dalton, S., Brooks, M.W., Littlewood, T.D., Evan, G.I. and Land, H. (1992) Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature, 359, 423-426.
3. Beijersbergen, R.L., Hijmans, E.M., Zhu, L. and Bernards, R. (1994) Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation. EMBO J., 13, 4080-4086.
4. Bello-Fernandez, C., Packham, G. and Cleveland, J.L. (1993) The ornithine decarboxylase gene is a transcriptional target of c-Myc. Prac. Natl Acad. Sci. USA, 90, 7804-7808.
5. Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R. and Magrath, I. (1993) Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Genet., 5, 56-61.
6. Blackwood, E.M. and Eisenman, R.N. (1991) Max: a helix-loop-helix ripper protein that forms a sequence-specific DNA-binding complex with Myc. Science, 251, 1211-1217.
7. Bryant, G.O., Martel, L.S., Burley, S.K. and Berk, A.J. (1996) Radical mutations reveal TATA-box binding protein surfaces required for activated transcription in vivo. Genes Dev., 10, 2491-2504.
8. Campanero, M.R. and Flemington, E.K. (1997) Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc. Natl Acad. Sci. USA, 94, 2221-2226.
9. Chen, P., Johnson, P., Sommer, T., Jentsch, S. and Hochstrasser, M. (1993) Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MATα2 repressor. Cell, 74, 357-369.
10. Chowdary, D.R., Dermody, J.J., Jha, K.K. and Ozer, H.L. (1994) Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol., 14, 1997-2003.
11. Ciechanover, A., DiGiuseppe, J.A., Bercovich, B., Orian, A., Richter, J.D., Schwartz, A.L. and Brodeur, G.M. (1991) Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Natl Acad. Sci. USA, 88, 139-143.
12. Clark, H.M., Yano, T., Otsuki, T., Jaffe, E.S., Shibata, D. and Raffeld, M. (1994) Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res., 54, 3383-3386.
13. Curran, T., Miller, A.D., Zokas, L. and Verma, I.M. (1984) Viral and cellular fos proteins: a comparative analysis. Cell, 36, 259-268.
14. Das, G., Hinkley, C.S. and Herr, W. (1995) Basal promoter elements as a selective determinant of transcriptional activator function. Nature, 374, 657-660.
15. Elledge, S.J. and Harper, J.W. (1998) The role of protein stability in the cell cycle and cancer. Biochim. Biophys. Acta, 1377, M61-M70.
16. Flinn, E.M., Busch, C.M.C. and Wright, A.P.H. (1998) myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol. Cell. Biol., 18, 5961-5969.
17. Galaktionov, K., Chen, X. and Beach, D. (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature, 382, 511-517.
18. Gross-Mesilaty, S., Reinstein, E., Bercovich, B., Tobias, K.E., Schwartz, A.L., Kahana, C. and Ciechanover, A. (1998) Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl Acad. Sci. USA, 95, 8058-8063.
19. Hann, S.R. and Eisenman, R.N. (1984) Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol., 4, 2486-2497.
20. Hateboer, G., Kerkhoven, R.M., Shvarts, A., Bernards, R. and Beijersbergen, R.L. (1996) Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev., 10, 2960-2970.
21. Henriksson, M., Bakardjiev, A., Klein, G. and Luscher, B. (1993) Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene, 8, 3199-3209.
22. Henriksson, M. and Luscher, B. (1996) Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res., 68, 109-182.
23. Hilt, W., Enenkel, C., Gruhler, A., Singer, T. and Wolf, D.H. (1993) The PRE4 gene codes for a subunit of the yeast proteasome necessary for peptidylglutamyl-peptide-hydrolyzing activity. Mutations link the proteasome to stress-and ubiquitin-dependent proteolysis. J. Biol. Chem., 268, 3479-3486.
24. Hoang, A.T., Lutterbach, B., Lewis, B.C., Yano, T., Chou, T.Y., Barrett, J.F., Raffeld, M., Hann, S.R. and Dang, C.V. (1995) A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107 and altered phosphorylation of the c-Myc transactivation domain. Mol. Cell. Biol., 15, 4031-4042.
25. Hochstrasser, M. (1996) Ubiquitin-dependent protein degradation. Annu. Rev. Genet., 30, 405-439.
26. Hofmann, F., Martelli, F., Livingston, D.M. and Wang, Z. (1996) The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev., 10, 2949-2959.
27. Kato, G.J., Barrett, J., Villa-Garcia, M. and Dang, C.V. (1990) An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol. Cell. Biol., 10, 5914-5920.
28. Kunkel, T.A., Roberts, J.D. and Zakour, R.A. (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol., 154, 367-382.
29. Lutterbach, B. and Hann, S.R. (1994) Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol. Cell. Biol., 14, 5510-5522.
30. Mora, P.T., Chandrasekaran, K., Hoffman, J.C. and McFarland, V.W. (1982) Quantitation of a 55K cellular protein: similar amount and instability in normal and malignant mouse cells. Mol. Cell. Biol., 2, 763-771.
31. Mumberg, D., Muller, R. and Funk, M. (1995) Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene, 156, 119-122.
32. Musti, A.M., Treier, M. and Bohmann, D. (1997) Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science, 275, 400-402.
33. Oren, M., Reich, N.C. and Levine, A.J. (1982) Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol. Cell. Biol., 2, 443-449.
34. Palmieri S., Kahn, P. and Graf, T. (1983) Quail embryo fibroblasts transformed by four v-myc-containing virus isolates show enhanced proliferation but are non-tumorigenic. EMBO J., 2, 2385-2389.
35. Papavassiliou, A.G., Treier, M., Chavrier, C. and Bohmann, D. (1992) Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun. Science, 258, 1941-1944.
36. Peukert, K., Staller, P., Schneider, A., Carmichael, G., Hanel, F. and Eilers, M. (1997) An alternative pathway for gene regulation by Myc. EMBO J., 16, 5672-5686.
37. Philipp, A., Schneider, A., Vasrik, I., Finke, K., Xiong, Y., Beach, D., Alitalo, K. and Eilers, M. (1994) Repression of cyclin D1: a novel function of MYC. Mol. Cell. Biol., 14, 4032-4043.
38. Pulverer, B.J., Fisher, C., Vousden, K., Littlewood, T., Evan, G. and Woodgett, J.R. (1994) Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene, 9, 59-70.
39. Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. and Goldberg, A.L. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78, 761-771.
40. 2-terminal domain of c-Myc increases transactivation of gene expression. J. Biol. Chem., 266, 23521-23524.
41. Smith-Sorensen, B., Hijmans, E.M., Beijersbergen, R.L. and Bernards, R. (1996) Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. J. Biol. Chem., 271, 5513-5518.
42. Spencer, C.A. and Groudine, M. (1991) Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res., 56, 1-48.
43. Tanaka, M. and Herr, W. (1990) Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell, 60, 375-386.
44. Tanaka, M., Lai, J.S. and Herr, W. (1992) Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter. Cell, 68, 755-767.
45. Traenckner, E.B., Wilk, S. and Baeuerle, P.A. (1994) A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J., 13, 5433-5441.
46. Treier, M., Staszewski, L.M. and Bohmann, D. (1994) Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell, 78, 787-798.
47. Tsurumi, C. et al. (1995) Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol. Cell. Biol., 15, 5682-5687.
48. Varshavsky, A. (1997) The ubiquitin system. Trends Biochem. Sci., 22, 383-387.
49. 1 cyclins for degradation by the ubiquitin proteolytic pathway. Cell, 86, 453-463.
50. Yaglom, J., Linskens, M.H., Sadis, S., Rubin, D.M., Futcher, B. and Finley, D. (1995) p34Cdc28-mediated control of Cln3 cyclin degradation. Mol. Cell. Biol., 15, 731-741.